BCA
BCRX icon

Burren Capital Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Burren Capital Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-13,900
Closed -$208K – 10
2015
Q2 		$208K Buy
13,900
+2,000
+17% +$22.7K 0.41% 17
2015
Q1 		$107K Buy
+11,900
New +$123K 0.39% 10

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Burren Capital Advisors's BCRX Position: Q3 2015 in Review

Burren Capital Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2015, closing a stake of 13,900 shares — an estimated $208K sold.

Burren Capital Advisors first reported a position in BCRX in Q1 2015 and held it in 2 quarters. The position peaked at $208K in Q2 2015. 124 funds tracked by Wall St. Rank hold BCRX as of Q3 2015.

  • Burren Capital Advisors reported no remaining BioCryst Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Burren Capital Advisors sold 13,900 BioCryst Pharmaceuticals shares in Q3 2015, an estimated $208K.
  • Burren Capital Advisors first reported a position in BioCryst Pharmaceuticals in Q1 2015 and held it in 2 quarters.
  • Burren Capital Advisors's BioCryst Pharmaceuticals position peaked at $208K in Q2 2015.
  • 124 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2015.

Based on Burren Capital Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.